Immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) inhibitors, have been used to treat various cancers, including non‐small cell lung cancer (NSCLC). The gene discussed is CD274; the disease is non-small cell lung carcinoma.